Ultragenyx is committed to supporting initiatives that provide impactful resources for the rare disease community, healthcare education, STEAM education, and local community organizations.
Since 2021, Ultragenyx has supported MitoCanada through generous donations totalling $119,000, supporting MitoScholars/+, Energy in Education and the Workplace, and MitoConnect programming. They have also sponsored our signature events, Walk NRoll 4 Mito in 2022 and 2023 and MitoSpin in 2023 and 2024. An enthusiastic group of employees joined MitoSpin in 2023.
“Ultragenyx was founded to advance innovative medicines for rare and ultrarare diseases that have never been treated before. We are delivering transformative therapies across multiple indications, and we have one of the most robust and diverse clinical pipelines in rare disease. Our focus is on doing the right things for patients both during development and commercialization to deliver on the promise of these therapies in a way that's meaningful for rare disease communities.”
Emil D. Kakkis, M.D., Ph.D.
Chief Executive Officer and President